ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
GSTP1	2950	15681469	-	Hypermethylation	-	-	8 proliferative endometruim; 20 simple hyperplasia; 11 complex hyperplasia; 20 atypical hyperplasia	97 (70 endometrioid adenocarcinoma + 12 endometrioid adenocarcinoma with focal squamoid differentiation; 3 with mucinous differentiation; 2 with secertory change as well as 7 high grade papillary serous carcinoma; 3 clear cell carcinoma)	31 to 97	56.9	Queen Mary Hospital; University of HongKong	-	1 (n=69); 2 (n=12); 3 (n=16)	[1] Hypermethylation of the GSTP1 gene promoter region may act as a dynamic regulation mechanism contributing to reduced GSTP1 expression; which is associated with myometrial invasion potential of the endometrial carcinoma. [2] The extent of myometrial invasion was found to be significantly correlated with both the methylation status (P = 0.009) and the protein expression (P = 0.036) of the GSTP1 gene. [3] 68.0% (66 of 97) of the cases showed reduced protein expression while 64% (16 of 25) showed reduced mRNA expression; 30.9% (30 of 97) of the cases demonstrated methylated alleles in at least one of the six methylation-specific polymerase chain reaction reactions. The methylation status significantly correlated with reduced protein expression (P = 0.008) and reduced mRNA expression (P = 0.003).	Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma.	The Journal of Molecular Diagnostics	7(1):8-16	2005
GSTP1	2950	15837751	-	Polymorphism	-	-	200	180 (154 endometrioid carcinoma+ 16 endometrioid carcinoma with focal squamoid differentiation+ 1 mucinous carcinoma+ 7 high-grade papillary serous )carcinoma+ 2 cleal cell carcinoma)	31 to 86 (patient); 27 to 82 (normal)	52.93 (patient); 54.2 (normal)	Department of Pathology; Queen Mary Hospital; University of Hong Kong	-	-	[1] The GSTP1 Ile(105)Val polymorphism was associated with an increased risk of endometrial cancer. [2] Statistical analysis showed that patients of valine allele carriers had 2.03-fold of increased risk of developing endometrial carcinoma (P < 0.01). The allele frequencies for the Ile and Val variants between the cancer cases and controls were also significantly different (P < 0.01; odds ratio; 1.59; 95% confidence interval; 1.13-2.23). Such association was shown in endometrial cancers as a group and in type I endometrioid adenocarcinoma but not the type II nonendometrioid adenocarcinoma. In addition; the Val allele was found significantly associated with high-grade endometrial cancer and/or endometrial cancer of deep myometrial invasion (P < 0.01).	Single nucleotide polymorphism of pi-class glutathione s-transferase and susceptibility to endometrial carcinoma.	Clinical Cancer Research	11(8):2981-5	2005